Each monthly installment examines an aspect of multiple myeloma care, including delivering the diagnosis, building trust, ...
Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...
Patients with multiple myeloma (MM) have a distinct pattern of second primary malignancy (SPM), with a markedly increased ...
SurvivorNet on MSN
CAR T-cell therapy and the hope for a cure in multiple myeloma
CAR T-cell therapy is a treatment that uses a patient’s own T cells, genetically reprograms them in a lab to recognize ...
LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92% achieving MRD negativity. Safety profile is favorable, with no severe ...
Topline data from the MagnetisMM-5 study demonstrate the superiority of elranatamab monotherapy over daratumumab plus pomalidomide and dexamethasone in double-class exposed multiple myeloma patients.
A healthcare provider shares her journey with multiple myeloma, discussing the physical, emotional and financial challenges ...
A new research paper was published in Volume 17 of Oncotarget on April 28, 2026, titled "Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis ...
CAR T, bispecific antibodies, and oral CELMoDs—expand options, protect QOL, and raise hopes of cure, notes Asya Nina ...
Results from the MagnetisMM-5 study showed that Elrexfio significantly improved progression-free survival, which means ...
In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained ...
A prespecified interim analysis showed statistically significant PFS improvement with elranatamab versus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results